Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups: FLOW Trial Post Hoc Analyses
BACKGROUND: Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups. METHODS: Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity. RESULTS: Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05). CONCLUSION: In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.
Authors
- Christian W. Mende (ORCID: https://orcid.org/0009-0002-3868-9969)
- Kenneth W. Mahaffey (ORCID: https://orcid.org/0000-0002-3791-2148)
- SHERIF J. MEHANNA
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Caroline Swift (ORCID: https://orcid.org/0000-0003-3192-1200)
- Richard E. Pratley (ORCID: https://orcid.org/0000-0002-2912-1389)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- David M. Charytan (ORCID: https://orcid.org/0000-0002-7695-3583)
- Robert S. Busch (ORCID: https://orcid.org/0009-0003-8634-7055)
- Søren Rasmussen
- Carlos Campos
Institutions
- Novo Nordisk (Denmark) (DK)
- University of Washington (US)
- AdventHealth Orlando (US)
- Inland Northwest Health Services (US)
- University of California San Diego (US)
- Diabetes Care Center (US)
- Stanford Medicine (US)
- Steno Diabetes Center Copenhagen (DK)
- Albany Med Health System (US)
- AdventHealth (US)
- New York University (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.2215/cjn.0000001242
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00